CEBPA and acute myeloid leukemia: In another study from Japan, a high frequency of CEBPA mutations (14.92%, 47/315) was observed, and CEBPAdm is an independent favorable prognostic risk factor in pediatric AML patients in multivariate analysis in the total patient cohort (36).